Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Medicus Pharma Ltd.MDCX · Entity 7770 | Chief Financial Officer | August 13, 2025 | August 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Medicus Pharma Ltd.
Report date August 13, 2025 · Filed August 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, no par value ("Common Shares")SEC Table I · non-derivative | Direct | 254,147 |
Reported balance
After 2025-08-13 transaction · row 1
1 source rowRow 1 · 2025-08-13 · Exercise / conversion · Acquired 125,000 · Balance 254,147 F1: Represents an exercise price of $1.16 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024. |
| Common SharesSEC Table I · non-derivative | Direct | 274,147 |
Reported balance
After 2025-08-13 transaction · row 2
1 source rowRow 2 · 2025-08-13 · Exercise / conversion · Acquired 20,000 · Balance 274,147 F2: Represents an exercise price of $3.95 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.81 · Expires 2028-10-24 | Direct | 0 |
Reported balance
After 2025-08-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-08-13 · Exercise / conversion · Disposed 125,000 · Balance 0 F1: Represents an exercise price of $1.16 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024. F3: The option was vested and was exercisable as of the Transaction Date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2029-12-17 | Direct | 0 |
Reported balance
After 2025-08-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-08-13 · Exercise / conversion · Disposed 20,000 · Balance 0 F2: Represents an exercise price of $3.95 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024. F3: The option was vested and was exercisable as of the Transaction Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an exercise price of $1.16 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024.
F2: Represents an exercise price of $3.95 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024.
F3: The option was vested and was exercisable as of the Transaction Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2025 Filed Aug 14, 2025 16:01 UTC | Medicus Pharma Ltd. MDCX · Entity 7770 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0000950142-25-002189 · es250667851_4-quinlan.xml · derivative · entry 4 Quinlan James P. · CIK 0002047493 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,000 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents an exercise price of $3.95 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024. F3 · derivative.exercise_date: The option was vested and was exercisable as of the Transaction Date. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 16:01 UTC | Medicus Pharma Ltd. MDCX · Entity 7770 | Exercise / conversionStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0000950142-25-002189 · es250667851_4-quinlan.xml · derivative · entry 3 Quinlan James P. · CIK 0002047493 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 125,000 shares Expires 2028-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents an exercise price of $1.16 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024. F3 · derivative.exercise_date: The option was vested and was exercisable as of the Transaction Date. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 16:01 UTC | Medicus Pharma Ltd. MDCX · Entity 7770 | Exercise / conversionCommon Shares | 20,000 | $2.75 | $55,000.00 |
DisclosureSEC source: 0000950142-25-002189 · es250667851_4-quinlan.xml · nonDerivative · entry 2 Quinlan James P. · CIK 0002047493 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Represents an exercise price of $3.95 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 16:01 UTC | Medicus Pharma Ltd. MDCX · Entity 7770 | Exercise / conversionCommon Shares, no par value ("Common Shares") | 125,000 | $0.81 | $101,250.00 |
DisclosureSEC source: 0000950142-25-002189 · es250667851_4-quinlan.xml · nonDerivative · entry 1 Quinlan James P. · CIK 0002047493 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents an exercise price of $1.16 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 17:17 UTC | Medicus Pharma Ltd. MDCX · Entity 7770 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000950142-25-002019 · es250658446_4-quinlan.xml · derivative · entry 2 Quinlan James P. · CIK 0002047493 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2030-07-22 F3 · derivative.exercise_date: The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.